Fri Oct 15 13:56:11 2004 Pacific Time
Hidden Epidemic of Monkey Virus Infections Arose From Contaminated
Polio Vaccines, Researcher Says
ROSEMEAD, Calif., Oct. 15 (AScribe Newswire) -- The Centers for
Disease Control and Prevention (CDC) was recently notified of an individual
infected with a monkey cytomegalovirus. Previous reports to CDC of
infections with viruses that originated from African green monkeys have
largely gone ignored, according to Dr. W. John Martin, M.D., Ph.D., founder
of the privately funded Centers for Complex Infectious Diseases in
Rosemead, California. "Public health officials have been very resistant,
since any airing of this topic will lead to the inevitable conclusion that
the government erred in accepting cytomegalovirus contamination of the
African green monkeys used in polio vaccine production."
In a 1972 joint government-industry study cited by Dr. Martin, cell
cultures from all 11 monkeys studied were contaminated with simian
cytomegalovirus. The scientific community was not informed of this finding.
In spite of industry's efforts to curtail contamination, Food and Drug
Administration (FDA) officials have confirmed that 3 of 8 licensed polio
vaccines released in 1976 have DNA of simian cytomegalovirus. Martin
referred to these results in an October 2002 meeting of the Institute of
Medicine. His manuscript entitled "DNA Analysis of a Stealth-Adapted Simian
Cytomegalovirus" was removed from the published proceedings of the
Martin contends that many of the diseases of epidemic proportions
in this county, including autism and attention deficit hyperactivity
disorder in children, as well as cancer, chronic fatigue, fibromyalgia and
Alzheimer's-like illnesses in adults, are caused by stealth-adapted
Stealth-adaptation is a process whereby cell-damaging viruses lose
components that are normally targeted by the immune system. Some, but not
all stealth-adapted viruses are derived from simian cytomegalovirus.
Increasingly, Martin is hearing of family illnesses of presumptive
infectious origin. He recently submitted a manuscript entitled "Complex
multi-system illnesses occurring within a family: Presumptive evidence for
an infectious disease process" to the CDC Journal of Emerging Infectious
Diseases, but its publication was declined. "It is hard to wake them up"
says Martin "and near impossible to break through the self protective
barrier of those who recognize that cytomegalovirus contaminated polio
vaccines used in Central Africa could have triggered the formation of the
AIDS virus. CDC has a collection of sera from polio vaccine immunized
African children that, under better leadership, would have been tested for
cytomegalovirus antibodies." Except for legal purposes, Martin has been
prohibited from communicating results of stealth virus testing to
individuals with complex unexplained illnesses. A petition recently sent to
CDC requesting that it tests autistic children for stealth-adapted viruses
was seemingly futile.
"The real tragedy of CDC," says Martin "is the public's expectation
that it will aggressively pursue every indication of potentially infectious
agents contributing to human diseases. Doing nothing is tantamount to
allowing disease to go unchecked. One way to establish dialogue with the
CDC is through the litigation process. Alternatively, a Congressman or
Senator willing to risk the ire of the pharmaceutical industry must insist
that CDC immediately address the issue of cytomegalovirus contamination of
polio virus vaccines and interview some of the many patients infected with
Dr. Martin says, "Now is the time for well
designed clinical studies to evaluate methods to prevent disease
transmission and to help restore normal brain function to stealth-adapted
virus infected individuals. The public needs to be informed and our
Government agencies need to respond."
More information, including copies of the manuscripts submitted to
the Institute of Medicine and CDC Journal of Emerging Infectious Diseases,
is available at www.s3support.com
CONTACT: W. John Martin, M.D., Ph.D., Director, Center for Complex
Infectious Diseases, Rosemead CA 91770, 626-616-2868, email@example.com
W. John Martin
o University of Sydney Australia . Graduated B.Sc. (Med) in 1963
and M.B., B.S. (M.D. equivalent) in 1965.
o Medical Residency at Royal Prince Alfred Hospital, Sydney,
o University of Melbourne . Ph.D. in Immunology 1967-1979.
o Post-doctoral training at the National Institutes of Allergy and
Infectious Diseases, NIH (1970); Pathology Department, Harvard Medical
School (1971), National Cancer Institute, NIH (1972) and University College
o Pathology Residency, National Naval Center, Bethesda Maryland
o Visiting Scientist and Expert National Cancer Institute, NIH,
Bethesda , MD 1/71-9/72; 2/74-1/76
o Supervisory Medical Officer GS-14 and Head, Oncology Unit,
Division of Virology, Bureau of Biologics, Food and Drug Administration,
NIH, Bethesda, MD 1/76-2/81
o Supervisory Medical Officer GS-15 and Head, Biological Resources
Branch, Biological Response Modifiers Program, National Cancer Institute,
NIH, Bethesda , MD 3/81-1/82
o Associate Professor of Pathology, Uniformed Services, University
of the Health Sciences, Bethesda , MD 1/82-6/85
o Professor of Pathology, University of Southern California School
of Medicine 7/85 - present. Tenured position with leave granted from 1996.
o Chief of Immunology/Immunopathology Unit, Section of Laboratories
and Pathology, Los Angeles County + University of Southern California
Medical Center, Los Angeles , CA 7/85-6/93. Unit name change to
Immunology/Molecular Pathology 7/88. Director of Flow Cytometry, 6/93 to
o Director of USC Infectious Diseases Laboratory and of USC
Molecular Pathology Laboratory within the USC Clinical Laboratories, USC
School of Medicine 1/88-10/95
o Founder and Director, Center for Complex Infectious Diseases,
Rosemead, California 91770 (A research and clinical laboratory testing
facility supported by donations and other funding managed by the National
o Diplomat of the American Board of Medical Laboratory Immunology
o Diplomat of the American Board of Pathology in Anatomic and in
Clinical Pathology 1984
o Special Competence Certification in Immunopathology, American
Board of Pathology, 1984
o Special Competence Certification in Medical Microbiology,
American Board of Pathology 1985
Media Contact: W. John Martin, M.D., Ph.D., Director, Center for
Complex Infectious Diseases, Rosemead CA 91770, 626-616-2868, firstname.lastname@example.org
J Autism Dev Disord. 2004 Oct;34(5):583-6.
Brief report: autistic disorder in three children with
Sweeten TL, Posey DJ, McDougle CJ.
Department of Psychiatry, Indiana University School of
Medicine, Indianapolis, IN 46202-4800, USA.
Previous research has identified a
relationship between autistic disorder (autism) and specific congenital
infections. Three cases of congenital or perinatal cytomegalovirus (CMV)
infection occurring in association with autism are described. Hypothetical
mechanisms relating congenital infection, such as CMV, to the development of
autism are discussed. A better understanding of the immunologic response to
certain congenital infections may provide important information pertaining to
the pathophysiology and etiology of autism in vulnerable individuals.
Medscape Medical News
Risk of Neurologic Abnormalities High in Prenatal CMV Infection
Laurie Barclay, MD
Sept. 9, 2002 — The neurologic outcome of primary maternal cytomegalovirus (CMV)
infection is bleak, according to a report published in the September issue
of Obstetrics and Gynecology. Even in women who chose not to abort, 19% of
infants had postnatal neurologic abnormalities despite negative prenatal
"Positive isolation of CMV accompanied by positive polymerase chain reaction
(PCR) values in amniotic fluid provided approximately 94% certainty of in
utero CMV infection," write Shlomo Lipitz, MD, and colleagues from Tel Aviv
University in Israel. "The risk of postnatal neurologic abnormalities was
19% (3 of 16) when there were no prenatal ultrasonographic abnormalities."
Among 50 pregnancies (51 fetuses) with proven primary maternal infection and
vertical transmission of CMV, 33 women (66%) elected pregnancy termination.
Ultrasound documented fetal abnormalities in 11 (21.5%) fetuses. Two of
these continued to term. Both were congenitally infected, and one had
neurologic abnormalities. Of 17 pregnancies (18 fetuses) which continued to
term, four fetuses had neurologic abnormalities, and three of these had
normal prenatal ultrasound. The remaining 14 had normal prenatal ultrasound
and no postnatal neurologic abnormalities.
"The severity of the sonographic abnormalities probably plays an important
role in prognosis," the authors write, recommending additional and larger
studies. "The significance of mild signs of fetal infection, e.g.
hyperechogenic bowel, in the presence of maternal infection is still
Obstet Gynecol. 2002;100:428-433
Reviewed by Gary D. Vogin, MD
Live Oral Poliovirus Vaccines and Simian
Biologicals Volume 30, Issue 3, September 2002, Pages 167-174
Ana M. Sierra-Honigmann and Philip R. Krausef1
Center for Biologics Evaluation and Research, Food and Drug Administration,
Building 29A Rm 1C16 29 Lincoln Drive, Bethesda, MD 20892, U.S.A.
Received 6 July 2001; accepted 5 February 2002. Available online 5 September
Live oral poliovirus vaccines (OPV) are often produced in primary
Cercopithecus monkey kidney (CMK) cells. The kidneys of these monkeys are
often latently infected with simian cytomegalovirus (SCMV), and CMK cultures
are frequently contaminated with SCMV. We tested human, monkey and rabbit
tissue culture systems, and found that MRC-5 cells are most sensitive for
detection of SCMV. To address the question of whether OPV could be
contaminated with infectious SCMV, we inoculated MRC-5 cells with
neutralized OPV manufactured in the United States between 1972 and 1998.
Infectious SCMV was not found in any of the vaccine lots tested. We also
used the polymerase chain reaction (PCR) to search for SCMV DNA in live oral
poliovirus vaccines; SCMV DNA sequences were found in several of the vaccine
lots manufactured prior to 1992.
Simian cytomegalovirus and contamination of oral poliovirus vaccines
Biologicals Volume 31, Issue 1, March 2003, Pages 63-73
Sally A. Baylis, , a, Nita Shaha, Adrian Jenkinsb, Neil J. Berryb and Philip
a Division of Virology, National Institute for Biological Standards and
Control, Blanche Lane, South Mimms, Potters Bar,Hertfordshire EN6 3QG, UK
b Division of Retrovirology, National Institute for Biological Standards and
Control, Blanche Lane, South Mimms, Potters Bar,Hertfordshire EN6 3QG, UK
Received 27 August 2002; accepted 15 October 2002. ; Available online 28
In the 1950s the use of primary rhesus macaque kidney cultures to propagate
poliovirus for vaccine production led to the contamination of vaccines with
simian virus 40 (SV40). African green monkey kidney (AGMK) cultures free of
SV40 were used as an alternative cell substrate for vaccine manufacture. In
this study we evaluate oral poliovirus seeds, vaccine bulks and vaccines
themselves for the presence of a common contaminant of AGMK cultures, simian
cytomegalovirus (SCMV). Using sensitive polymerase chain reaction (PCR)
techniques, nearly half of the samples analysed were found to be
contaminated with SCMV sequences. However, vaccine bulks, positive by PCR
for SCMV failed to show any evidence of infectious virus in these studies.
One poliovirus vaccine and one seed, propagated on rhesus macaque kidney
cultures were found to be positive for the rhesus monkey CMV by PCR.
By KATRINA WOZNICKI, UPI Science News
BIRMINGHAM, Ala. (UPI) - A common human virus might have some role in the
development of colon cancer, according to a new, small study released
Preliminary findings from researched conducted at the University of Alabama
in Birmingham suggest the cytomegalovirus, or CMV, a widespread organism
particularly dangerous to people with weakened immune systems, could be
associated with the cellular breakdown that leads to colon cancer. "This
virus is strongly associated with malignant brain tumors," lead researcher
Dr. Charles S. Cobbs, also a neurosurgeon with the Birmingham VA Medical
Center, told United Press International. "The more I learned about virus,
the more I realized it had many properties important for cancer in general."
As described in the Nov. 16 issue of the British journal The Lancet, Cobbs
and his team took colorectal polyps, tumors and surrounding healthy cells
from 29 patients. They found proteins from the cytomegalovirus in
approximately 80 percent of the polyps and in about 85 percent of the colon
"I'm not trying to say this virus is causal in colon cancer," Cobbs said."
I've just made a preliminary observation ... whether or not it's influencing
the cancer remains to be determined." The virus might be inducing unwanted
cell behavior that could lead later to uncontrollable cell growth or cancer,
Cobbs explained, but more study is needed to confirm these findings.
Cytomegalovirus resides in about 50 to 80 percent of the U.S. population,
Cobbs said, and age and socioeconomic status are risk factors. The virus
also can cause ulcers, he explained. It is a relative of the herpes virus
and, like herpes or chicken pox, when an individual contracts it the virus
cannot be eradicated. It can lie dormant in a person for years or even
decades and not cause any harm.
In people with compromised immune systems, however, such as AIDS or
chemotherapy patients, the virus can wreak havoc on the gastrointestinal
tract, the eyes and the brain, Cobbs said.
Although the virus is common, Cobbs said people should not be worried about
getting cancer from it. "There's probably at least 15 coincidental things
that all have to occur at once" involving this virus before cancer develops,
Viruses have been implicated in cancers before, but Dr. Gerard Blobe, an
assistant professor of medicine in pharmacology and cancer biology at Duke
University Medical Center in Durham, N.C., said previous studies on the
cytomegalovirus have been mixed or inconclusive.
"It would be a little surprising" if these findings proved to be true, he
told UPI. "They've certainly been looking for causes of colon cancer. It is
surprising just because it goes in contrast in what other investigators have
shown, but have not really reported."
In fact, Blobe said of the herpes virus family, cytomegalovirus is thought
to be one that does not influence cancer. "I think this study would need to
be investigated in larger population of individuals before we truly believe
this is a cause for colon cancer," he said.
BUT FANTASTIC NEWS!
First, The Bad News
It is very bad. People who live in North America are at a far greater
risk today of contracting anything from colds to cancer, from headaches to
heart attacks, than they were last year! The immune system is the main link
to most health problems. The stronger the immune system, the less risk
people have of any disease. The weaker the immune system, the greater the
risk of getting any disease. Everyone develops cancer cells on a daily
basis, and viruses and bacteria are probing our defenses every minute.
How bad is it? Your Natural Killer Cells (NKC) are the most active
part of your immune system, and are your first line of defense against
bacteria, viruses, and cancer. Between 1981 and 1991, Natural Killer Cells
in the average American declined 1% a year—from 1991 to 1997, the loss
accelerated to 3% a year, a 26% drop in just 16 years! A bad night's sleep
can lower it another 30% for a day or two. Several spoons of sugar from soft
drinks and goodies can lower it another 50% for up to five hours—all day for
the many who indulge their "sweet tooth" several times a day. Tests of
dieters saw a drop of 50%! (Dieters who exercised 40-60% maximal intensity
did not suffer this loss—but all who exercise strenuously for more than an
hour have more infections in the next week.) Ill people run a very low NKC
count, inviting further illness. Many drugs and opiates interfere with the
immune system [opiates increase apoptosis (cell death) of T–lymphocytes from
the norm of 5% to 30%]. As a result, death by infections other than HIV has
"Researchers have shown for the first time that people who developed the
fatty blockages that mark heart disease had an infection first...Many
studies have linked heart disease with infections by bacteria or
viruses...several teams have found Chlamydia Pneumoniae in the hardened
plaques blocking the arteries, as well as Helicobacter pylori...and a virus
known as cytomegalovirus (herpes-5)." Chlamydia pneumoniae, which infects
sinuses, was found in 17 of 19 Alzheimer's victims' brains! Viruses cause
blood to sludge, causing clotting which can lead to strokes within the
following two weeks. Encephalitis is caused by the West Nile and St. Louis
viruses, enteroviruses, herpes, varicella, LaCrosse, and James Canyon
viruses. Some are mosquito-transmitted; others, such as herpes, are spread
person-to-person. Lipkin, in 1995, found small RNA horse microbes, called
borna viruses, in the brains of people who had suffered from either
schizophrenia or bipolar disorder. It has been implicated in some forms of
depression, and several laboratories have shown that the hardy microbes
thrive for decades in the bodies of unfortunate human beings. Additionally,
a second virus, toxoplasma gondii, has been found in people with
Schizophrenia. This is the cat virus acquired from handling cat feces. Human
pavrovirus B19 has been linked to arthritis, MS, and Sickle Cell Anemia.
Breast cancer tissue in far higher percentage (33%) than healthy breast
tissue (2%) contains a retroviruses identical with mouse mammary tumor
Dr. Hans A. Nieper, renown German researcher, and associates, completed a
four year tracking program that convinces them there is aggressive, viral
activity in 90% of all malignancies, colitis, rheumatoid arthritis,
scleroderma, multiple sclerosis, and Lou Gehrig's disease (ALS). He
concludes that a virus is active in most diseases. He tracked Herpes I and
II and the cytomegalovirus (Herpes–V). He considers the cytomegalovirus to
be particularly problematic as it replicates in the lymph cells and leaves
its genetic information there to disrupt normal cellular information for
years to come. HSV-I occasionally travels to the brain and kills (R. L.
Ashley, UW School of Medicine). Researchers at the University of California
recently identified a virus in ALS. The bacteria, mycoplasma, infests the
joints in rheumatoid arthritis, and salmonella and Lyme disease can trigger
an autoimmune attack on joints. Measles virus is found in the colon of
Autism and Crohn's. Parasites were found in 93% of Chronic Fatigue Immune
Deficiency Syndrome (CFIDS) (J Nutritional Med, 1990; 1:27-31) and in many
The Coxsackie virus is implicated in many diseases (Type I, juvenile
diabetes). In the USA, the retrovirus sickens 3,000,000 children, sending
500,000 to the doctor and 75,000 to the hospital because formula does not
provide the needed substrate (found in Mother's milk) for the glycoprotein, Lactadherin, that coats the virus preventing it from infecting cells (David
Newburg Ph.D., Shiver Center for Mental Retardation, Massachusetts). A type
of retrovirus is involved in HIV, Lupus, and other diseases. Helicobacter
pylori has been implicated in 95% of ulcers, in gastritis, excessive stomach
acid, stomach cancer, heart disease, and possibly certain allergies. Herpes
Virus–VI has been identified in the brain (73%) and blood (56%) of Multiple
Sclerosis patients. Viruses act to "trigger" other diseases in prone
individuals. Many bacteria have become resistant to our most powerful
This means that not just some of us, but all of us are at great risk to
diseases. Close to 100% of us have heart disease that began when we were
children—it just takes 40 years to develop. Of the teenagers who died during
the Viet Nam war, 100% had signs of clogging arteries! No one is fully
healthy any more, not even if you look and feel healthy and your doctor says
your blood test is great! Dr. Harry Alsleben has shown that blood tests will
not predict imminent death, nor will they change after death! How can they
Here's further evidence: 50% of all deaths in America are from
circulatory/heart disease, 33% from cancer, and 12% from diabetes (that's
95%). These were rare conditions just decades ago. In addition, we now have
rampant allergies, arthritis, asthma, Autism, Chronic Fatigue, Fibromyalgia,
antibiotic resistant bacteria (some of which actually eat antibiotics), and
many very dangerous mutant viruses.
Related Articles,Links Herpesviruses in brain and Alzheimer's disease.
Lin WR, Wozniak MA, Cooper RJ, Wilcock GK, Itzhaki RF.
Department of Optometry and Neuroscience, UMIST, Manchester, UK.
It has been established, using polymerase chain reaction (PCR), that herpes
simplex virus type 1 (HSV1) is present in a high proportion of brains of
elderly normal subjects and Alzheimer's disease (AD) patients. It was
subsequently discovered that the virus confers a strong risk of AD when in
brain of carriers of the type 4 allele of the apolipoprotein E gene
(apoE-epsilon4). This study has now sought, using PCR, the presence of three
other herpesviruses in brain:human herpesvirus 6 (HHV6)-types A and B,
herpes simplex virus type 2 (HSV2)and cytomegalovirus (CMV). HHV6 is present
in a much higher proportion ofthe AD than of age-matched normal brains (70%
vs. 40%, p=0.003) and there is extensive overlap with the presence of HSV1
in AD brains, but HHV6, unlike HSV1, is not directly associated in AD with
apoE-epsilon4. In 59% of theAD patients' brains harbouring HHV6, type B is
present while 38% harbour both type A and type B, and 3% type A. HSV2 is
present at relatively low frequency in brains of both AD patients and
normals (13% and 20%), and CMVat rather higher frequencies in the two groups
(36% and 35%); in neither case is the difference between the groups
statistically significant. It is suggested that the striking difference in
the proportion of elderly brains harbouring HSV1 and HSV2 might reflect the
lower proportion of people infected with the latter, or the difference in
susceptibility of the frontotemporal regions to the two viruses. In the case
of HHV6, it is not possible to exclude its presence as an opportunist, but
alternatively, it might enhance the damage caused by HSV1 and apoE-epsilon4
in AD; in some viral diseases it is associated with characteristic brain
lesions and it also augments the damage caused by certain viruses in cell
culture and in animals.
Copyright 2002 John Wiley& Sons, Ltd.
PMID: 12115887 [PubMed - indexed for MEDLINE]
Stealth Virus Infected Children: Brain Damage and the Development of Chronic
Fatigue Syndrome and Fibromyalgia
W. John Martin, M.B., B.S., Ph.D. Center for Complex Infectious Diseases
3328 Stevens Avenue, Rosemead, California USA 91770 e-mail
Atypically structured, vacuolating cytopathic stealth viruses exist and can
induce multi-system illnesses, including severe brain disease. DNA
sequencing studies on an African green monkey simian cytomegalovirus (SCMV)-derived
stealth virus has heightened concerns for the potential devastating effects
of stealth viruses on living organisms. The prototype stealth virus has lost
the major antigenic targets for recognition by cytotoxic T lymphocytes. More
impressively, it has captured, amplified and mutated both cellular and
bacterial genetic sequences. The term "viteria" has been introduced for
viruses containing bacterial sequences. Stealth viruses have been cultured
from babies born to infected mothers and from children with a variety of
neurological, psychiatric, allergic and neoplastic diseases. The cytopathic
changes seen in stealth virus cultures correlate well with the vacuolating
cellular damage observed on histological sections of brain tissues obtained
on biopsy and on autopsy. Studies to combat the spread of stealth viruses
and to effectively treat those already infected are clearly warranted.
Additional information is available from the internet at
www.ccid.org Poliovirus Vaccine Contamination One of society's highest
obligations is the protection of its children. Vaccine programs provide a
proven method for childhood disease prevention. The safety of such programs
has been entrusted to vaccine manufacturers and to government regulatory
agencies. Although widely touted as the major medical triumph of the 20th
century, the development of viral vaccines has elements of less than stellar
performance. The discovery in 1960 of live SV-40 virus contamination in
formalin-treated poliovirus vaccine, produced in kidney cells cultures from
rhesus monkeys, did not lead to an immediate recall of the contaminated
vaccines. Rather, the production method was switched to the use of kidney
cells from the less well characterized African green monkeys. This switch in
monkey species was soon followed by the decision to forgo formalin
inactivation by using a weakened (attenuated) live strain of poliovirus (1).
Persisting concerns regarding contaminating viruses in the live poliovaccine
led in 1972 to a joint study between the vaccine manufacturer and the United
States Food and Drug Administration (FDA). Kidney cultures from all 12
monkeys tested grew African green monkey simian cytomegalovirus (SCMV). Only
4 of the SCMV isolates were detectable using the regular methods for virus
detection (2). No changes in testing methodology were imposed, nor was the
scientific community alerted to the findings. An explanation that was
subsequently offered was that information about the study was deemed to be
proprietary. The results of this earlier study were, however, not even
conveyed to FDA scientists who, in 1977, notified the Director of the FDA's
Bureau of Biologics that certain poliovaccine lots contained unexplained
non-cellular DNA; and were, therefore, potentially virally contaminated. The
issue of SCMV contamination of poliovirus vaccines was again raised with the
FDA in May 1995. I was then working as a virologist at the University of
Southern California. I had developed tissue culture methods that clearly
indicated the presence of atypical viruses in patients with complex
neurological diseases (3-7). The viruses were striking in that they failed
to evoke an inflammatory reaction in the patients from whom they were
isolated. They were termed stealth viruses on this basis, and seemingly they
lacked target antigens for recognition by the body's cellular immune
system. Sequencing studies on a stealth virus strongly suggested it had
originated from SCMV. Several meetings with FDA and Center for Disease
Control and Prevention (CDC) officials pointed to their unwillingness to
allow any outside review of vaccine safety procedures. For example, a simple
request to review histological slides of neurological tissue of monkeys
inoculated with poliovaccine was refused, again on the basis that it was
proprietary information. Noteworthy was the admission that the vaccines were
routinely tested in rhesus monkeys because African green monkeys commonly
show evidence of neurological disease. Moreover, even in rhesus monkeys, the
vaccine was said to induce considerable neurological damage, although less
than that induced by non-attenuated poliovirus. The actual SCMV-related
sequence data were published in a respected virology journal in July 1995
(8). The article aroused the interest of anti-vaccine consumer groups.
Through the efforts of one of these groups, I was invited to attend a
vaccine safety meeting of the
Institute of Medicine, National Academy of Sciences (9). The open meeting
held on November 6, 1995 was followed the next day by an "executive
session." I was later informed that several Industry-connected individuals
at this meeting were "furious" that I was allowed to speak. A "watered down"
account of what I said subsequently appeared in the official report of the
meeting. Some insight into the lack luster nature of the existing regulatory
system was provided by several brief interchanges with Government and other
officials during the last several years. For example, I was asked whether
formalin treatment would inactivate stealth viruses. My response was that I
did not know. The chairman of the National Immunization Advisory Committee
suggested the advocacy of a split protocol in which both formalin
inactivated and live attenuated poliovaccine would provide the necessary
time window for the manufacturer of the inactivated vaccine to develop the
stocks required for a complete switch. True to his suggestion, the official
switch to inactivated vaccine is scheduled for January 2000. Of course,
those "in the know" would have already switched to the inactivated vaccine.
An FDA reform bill was being considered by Congress in 1997. I suggested
that the bill include the provision that "If a safety issue is identified in
the regulation of a biological product, then Industry would waive its
proprietary protection so that the information could be made available to
the scientific community." The suggestion was well received by the counsel
for the House Commerce Committee. It was soon dropped, however, when support
was not forthcoming from Industry, FDA or the American Medical Association
(AMA). In speaking
with an AMA lobbyist, I understood they "would not want the public to know
that their doctors were not in the knowledge loop." I once asked industry
personnel involved in poliovaccine production whether they were still
encountering SCMV in poliovaccine production lots. After some hesitation
that disappeared as we all identified ourselves as parents, the
straightforward answer was "not infrequently." Armed with this information I
again requested an FDA official to please use modern techniques, such as the
polymerase chain reaction (PCR), to screen poliovaccine lots for SCMV. "We
would not know what to do with a positive result" was his answer. Sequencing
Studies on the SCMV-Derived Stealth Virus Continued sequencing of the
prototype SCMV-derived stealth virus have helped substantiate the original
suggestion that stealth adapted viruses lack the critical target antigens
for cellular immune recognition (10-11). The virus has a fragmented viral
genome (11). While the various fragments cover extensive regions of a
typical cytomegalovirus, it is missing sequences that correspond to the
known major viral antigens targeted by anti-cytomegalovirus cytotoxic T
lymphocytes. Other regions of the cytomegaloviral genome are unevenly
distributed, with certain viral genes being markedly over represented. When
multiple copies of a gene were identified, it was not uncommon to see minor
sequence differences indicating an "error-prone" replication process
(10-11). An overview of the viral sequence data is that approximately
two-thirds of the clones contain sequences that correspond to
cytomegaloviral genes (10). Where direct comparisons could be made, the
genetic sequences matched more closely to rhesus monkey cytomegalovirus than
to human cytomegalovirus. Even closer homology could be shown between the
stealth virus and the limited known sequences of SCMV. The data are
unequivocal that the virus had originated from an SCMV and hence from a
poliovaccine (8,10-11). The question that arose was how could such a
fragmented viral genome, lacking certain viral genes while over expressing
other viral genes, retain and/or regain its ability to be cytopathic for
cells. A partial answer to this question came from analyses of the genes
that did not correspond to those of a cytomegalovirus. Several genes were
apparently directly incorporated from infected cells. These genes frequently
contained short stretches of highly reiterated cellular sequences (12). One
set of cellular genes was particularly noteworthy. They corresponded to
three copies of a gene that encode a chemokine (13). While the cellular DNA
for this gene contain introns, the assimilated genes were lacking introns
and had, therefore, been 'captured" as RNA sequences. This finding provided
direct evidence for reverse transcription (that is RNA to DNA) in the
reconstruction of cytopathic stealth viruses. This process was consistent
with the error-prone replication of the stealth virus. Among the cellular
genes identified within the stealth virus, were also genes with potential
oncogenic (cancer causing) activity (13). This finding highlighted ongoing
observations that stealth adapted viruses were being repeatedly detected in
both children and adults with various cancers (14 and unpublished
observations). An additional challenging observation was the finding that
some of the incorporated sequences had clearly been captured from bacteria
(15). The bacterial genes covered a wide range of metabolic functions that
could enhance bacterial growth (16). This observation was soon followed by
the detection of atypical bacteria within the flora of stealth virus
infected patients. Moreover, infectious agents could be released from such
bacteria and cause cytopathic effects when transferred to human and to
animal cells. The presence of bacterial sequences within viruses infectious
for human and animal cells represents a novel life form that has been termed
viteria. The prospect exists for metabolically empowered bacteria to
establish an increasing presence within nature with potentially devastating
biological consequences. The notion that viteria represents "Nature's
biological weapons program" is not too far fetched. Information concerning
the existence of viteria and their potential Public health consequences was
conveyed to CDC, FDA, NIH and the US Congress. Responses are still being
awaited from these agencies. Viteria: An Explanation for Serological and
Molecular Findings of Multiple Pathogens in Adults and Children with Chronic
Fatigue and Related Illnesses The recombination of viral, bacterial and
cellular genes within broadly infectious viteria could help explain much of
the confusion surrounding the cause of chronic fatigue like illnesses in
adults, children and household pets. Depending upon the focus of the
research, various investigators have ascribed these illnesses to different
types of pathogens. Some of the early reports relied upon high antibody
titers to Epstein-Barr virus (a type of herpesvirus). Others have noted
antibodies reactive with
human herpesvirus-6, human herpesvirus-7, human T lymphotropic virus,
parvovirus, Borna virus, modified endogenous retroviruses, enteroviruses,
including poliovirus, and hepatitis C viruses (17-25). Using molecular
techniques, data have been obtained suggesting the presence of mycoplasma
species, Chlamydia, Rickettsiae, Brucella and even Borrelia bacteria
(26-30). These data are consistent a broad family of viteria that have, and
are continuing to, capture, amplify and mutate viral, cellular, bacterial
even fungal genes. Among the cellular/viral genes are likely to be genes
encoding the reverse transcriptase of endogenous retroviruses. Although,
infection can pass between individuals, including human: animal
transmissions, via infected bacteria, the primary brain associated illness
is viral not bacterial. The apparent clinical benefits that may occur
following antibiotic therapy are potentially explainable by the known
capacity of certain antibiotics to modulate chemokine mediated viral
activation and replication. Viteria Detection Systems The molecular
diversity of viteria has helped underscore the value of tissue culture as a
primary detection assay. In a relatively straightforward procedure, cells
from patients are incubated with normal human and/or animal fibroblasts. The
cultures are observed for the development of a vacuolating cytopathgic
effect (CPE). For controls, blood samples are obtained from healthy blood
donors. None of the controls are expected to yield a positive CPE. In
contrast, stealth virus infected patients will typically yield a clearly
positive culture. Once established, the cultures can be screened using
various immunological and molecular based assays. In particular, cells
undergoing CPE will typically stain with polyclonal antisera reactive with
various herpesviruses. Similarly, low stringency polymerase chain reaction (PCR)
will typically yield multiple products that can be isolated, cloned and
sequenced. Semi-quantitative cultures can also be used to assess efficacy of
various therapies including
chemokine modulating agents and anti-viral drugs. It is also appropriate to
screen the bacterial flora of infected individuals for atypical bacteria. If
necessary, these can be treated directly using antibiotics and probiotics.
Clinical Studies During the last decade, I have written several clinical
articles describing stealth virus infected patients with complex illnesses.
The patients have included children with autism, adults with psychotic
disease and several individuals with chronic fatigue/fibromyalgia syndrome.
Many of the articles had been summarily dismissed when submitted to major
medical journals. The suggestion of a linkage to vaccine use or of community
wide epidemics has been unsettling to many reviewers. Still the work has
appeared in peer reviewed publications and has been presented at various
meetings (31-36). For example, a recent publication (36) described a stealth
virus infected child whose illness began in 1997 as a behavioral problem. It
took over seven months before the illness was attributed by his parents,
both of whom were physicians, to brain damage. Even then a qualified
neurologist was unable to detect impaired motor or sensory functions. Yet
magnetic resonance imaging (MRI) confirmed extensive sub-cortical brain
damage. A brain biopsy showed marked vacuolating/spongiform change. The
child's clinical condition progressively deteriorated. He was examined at
several major medical centers where it was wrongly concluded that he had a
genetic disease from which he would soon die. He was shown to be stealth
virus infected by tissue culture and significantly improved with ganciclovir
therapy, although he still had major residual deficits. In spite of several
courses of anti-viral therapy, with and without steroids, he subsequently
succumbed to overt cerebral swelling and herniation. Other fatal cases have
included a young adult initially diagnosed as having a psychotic illness.
Four years into this illness, she had an acute exacerbation with coma and
massive brain damage (32). Her cerebrospinal fluid grew out a stealth virus
closely related to that of the prototype SCMV-derived virus. Another patient
with a fatal illness and positive CSF findings died with evidence of a
cerebral vasculitis (33). Virally infected newborn children have variously
presented with an acute viral-like syndrome with hepatomegaly,
thrombocytopenia, choroid plexus hemorrhage or with more subtle changes
comprising unexplained seizure activity and/or delayed neurological
development. At least one child, born to a mother with a chronic fatigue
like illness, died from a sudden infant death syndrome, two weeks following
routine vaccination. Young children have presented with autism, attention
deficit and hyperactivity, learning and other behavioral disorders. The
association of stealth virus with autism was clearly established in
controlled double blind studies. Whereas none of 19 control blood samples
tested positive, 13 of 18 children with autism yielded repeated positive
stealth virus cultures. Other culture positive clinical groups have included
in-patients in psychiatric institutions, cancer patients, including
essentially 100% of patients diagnosed with multiple myeloma, auto-immune
illnesses, including systemic lupus erythematosus, rheumatoid arthritis and
multiple children diagnosed as having chronic fatigue syndrome. With all of
these illnesses, stealth viral infection is viewed as a major contributing
factor, complicated by the overlay of auto-immune, allergic and/or
neoplastic processes. Conclusions An essential theme of this presentation is
the apparent lack of responsiveness on the part of those entrusted with the
nation's Public Health. While it can be argued that adults need to compete
for allocated resources applied to various illnesses, it is difficult to
understand the indifference shown to health issues affecting children. Where
is the concern that a biopsy-proven childhood viral infection was not
recognized at major medical centers? Where is the interest in the many other
children who have tested positive for stealth viruses? Why the lack of
discussion about possible brain damage causing national tragedies such as
school shootings, and the increasing prevalence of autism, attention
deficit, asthma and sudden infant death syndrome? Are stealth virus infected
patients populating our psychiatric institutions, allergy clinics and even
our cancer wards? The world and, in particular, its children appear to be at
risk for stealth adapted viruses. The contribution of vaccines to the
formation and dissemination of these viruses should be an open topic for
scientific discussion. This is not occurring with those presently in charge
of overseeing the safety of the Nation's immunization program. References 1.
Paul JR. A history of poliomyelitis. Yale University Press, New Haven, 1971.
2. Unpublished documentation. 3. Martin W.J. Viral infection in CFS
patients. in "The Clinical and Scientific Basis of Myalgic Encephalomyelitis
Chronic Fatigue Syndrome." Byron M. Hyde Editor. Nightingale Research
Foundation Press. Ottawa Canada pp 325-327, 1992. 4. Martin WJ, Zeng LC,
Ahmed K, Roy M. Cytomegalovirus-related sequence in an atypical cytopathic
virus repeatedly isolated from a patient with chronic fatigue syndrome. Am J
Pathol. 1994;145:440-51. 5. Martin WJ. Stealth viruses as neuropathogens.
CAP Today. 1994 ;8:67-70. 6. Martin WJ, Glass RT. Acute encephalopathy
induced in cats with a stealth virus isolated from a patient with chronic
fatigue syndrome. Pathobiology. 1995;63:115-8. 7. Martin WJ. Stealth virus
isolated from an autistic child. J Autism Dev Disord. 1995;25:223-4. 8.
Martin WJ. Presentation to the Institute of Medicine Meeting on Vaccine
Safety, November 6th, 1995. Web site www.ccid.org 9. Martin WJ, Ahmed KN,
Zeng LC, Olsen J-C, Seward JC, Seehrai IS. African Green Monkey Origin of
the Cytopathic 'Stealth Virus' Isolated from a Patient with Chronic Fatigue
Syndrome, Clin Diag Virol 1995; 4: 93-103. 10. Martin WJ. Stealth adaptation
of an African green monkey simian cytomegalovirus. Exp Mol Pathol.
1999;66:3-7. 11. Martin WJ. Genetic instability and fragmentation of a
stealth viral genome. Pathobiology. 1996;6:9-17. 12. Martin WJ. Cellular
sequences in stealth viruses. Pathobiology. 1998;66:53-8. 13. Martin WJ.
Melanoma growth stimulatory activity (MGSA/GRO-alpha) chemokine genes
incorporated into an African green monkey simian cytomegalovirus-derived
stealth virus. Exp Mol Pathol. 1999; 66:15-8. 14. Gollard RP, Mayr A, Rice
DA, Martin WJ. Herpesvirus-related sequences in salivary gland tumors. J Exp
Clin Can Res.1996;15: 1-4. 15. Martin WJ. Bacteria-related sequences in a
simian cytomegalovirus-derived stealth virus culture. Exp Mol Pathol. 1999;
66:8-14. 16. Martin WJ. Viteria: Bacterial sequences in animal and human
viruses. J Degenerative Diseases 1999;1:7-10. 17. Jones JF Epstein-Barr
virus and the chronic fatigue syndrome: a short review. Microbiol Sci
1988;5:366-9. 18. Di Luca D, Zorzenon M, Mirandola P, Colle R, Botta GA,
Cassai E. Human herpesvirus 6 and human herpesvirus 7 in chronic fatigue
syndrome. J Clin Microbiol 1995;33:1660-61. 19. Jacobson SK, Daly JS, Thorne
GM, McIntosh K. Chronic parvovirus B19 infection resulting in chronic
fatigue syndrome: case history and review. Clin Infect Dis 1997 ;24:1048-51.
20. Behan PO, Behan WM, Gow JW, Cavanagh H, Gillespie S. Enteroviruses and
postviral fatigue syndrome. Ciba Found Symp 1993;173:146-54. 21. Bruno RL,
Creange SJ, Frick NM. Parallels between post-polio fatigue and chronic
fatigue syndrome: a common pathophysiology? Am J Med 1998 ;105:66S-73S. 22.
DeFreitas E, Hilliard B, Cheney PR, Bell DS, Kiggundu E, Sankey D,
Wroblewska Z, Palladino M, Woodward JP, Koprowski H. Retroviral sequences
related to human T-lymphotropic virus type II in patients with chronic
fatigue immune dysfunction syndrome. Proc Natl Acad Sci U S A
1991;88:2922-6. 23. Holmes MJ, Diack DS, Easingwood. RA, Cross JP, Carlisle
B. Electron microscopic immunocytological profiles in chronic
fatigue syndrome. J Psychiatr Res 1997;31:115-22. 24. Nakaya T, Takahashi H,
Nakamur Y, Kuratsune H, Kitani T, Machii T, Yamanishi K, Ikuta K. Borna
disease virus infection in two family clusters of patients with chronic
fatigue syndrome. Microbiol Immunol 1999;43:679-89. 25. Barkhuizen A, Rosen
HR, Wolf S, Flora K, Benner K, Bennett RM Musculoskeletal pain and fatigue
are associated with chronic hepatitis C: a report of 239 hepatology clinic
patients. Am J Gastroenterol 1999;94:1355-60. 26. Vojdani A, Choppa PC,
Tagle C, Andrin R, Samimi B, Lapp CW. Detection of Mycoplasma genus and
Mycoplasma fermentans by PCR in patients with ChronicFatigue Syndrome. FEMS
Immunol Med Microbiol 1998;22:355-65. 27. Chia JK, Chia LY. Chronic
Chlamydia pneumoniae infection: a treatable cause of chronic fatigue
syndrome. Clin Infect Dis 1999;29:452-3. 28. Penttila IA, Harris RJ, Storm
P, Haynes D, Worswick DA, Marmion BP. Cytokine dysregulation in the
post-Q-fever fatigue syndrome. QJM 1998 ;91:549-60. 29. Ottenweller JE,
Natelson BH, Gause WC, Carroll KK, Beldowicz D, Zhou XD, LaManca JJ. Mouse
running activity is lowered by Brucella abortus treatment: a potential model
to study chronic fatigue. Physiol Behav 1998;63:795-801. 30. Gaudino EA,
Coyle PK, Krupp LB. Post-Lyme syndrome and chronic fatigue syndrome.
Neuropsychiatric similarities and differences. Arch Neurol 1997; 54:1372-6.
31. Martin WJ. Detection of RNA sequences in cultures of a stealth virus
isolated from the cerebrospinal fluid of a health care worker with chronic
fatigue syndrome. Case report. Pathobiology. 1997;65:57-60. 32. Martin WJ.
Simian cytomegalovirus-related stealth virus isolated from the cerebrospinal
fluid of a patient with bipolar
psychosis and acute encephalopathy. Pathobiology. 1996;64:64-6. 33. Martin
WJ. Stealth viral encephalopathy: report of a fatal case complicated by
cerebral vasculitis. Pathobiology. 1996;64:59-63. 34. Martin WJ. Severe
stealth virus encephalopathy following chronic-fatigue-syndrome-like
illness: clinical and histopathological features. Pathobiology. 1996;64:1-8.
35. Martin WJ, Anderson D. Stealth virus epidemic in the Mohave Valley. I.
Initial report of virus isolation. Pathobiology. 1997;65:51-6. 36. Martin
WJ,Anderson D. Stealth virus epidemic in the Mohave Valley: Severe
vacuolating encephalopathy in a child presenting with a behavioral disorder.
Exp Mol Pathol. 1999; 66:19-30. Source: http://www.ccid.org/stealth/publications/braindamage.htm
Cytomegalovirus is present in a very high proportion of brains from vascular
Lin WR, Wozniak MA, Wilcock GK, Itzhaki RF. Molecular Neurobiology
Laboratory, UMIST, Manchester, M60 1QD, United Kingd= om.
Neurobiol Dis 2002 Feb;9(1):82-7
We previously found that herpes simplex type 1 virus (HSV1), when present in
brain of carriers of the apolipoprotein E type 4 allele is a strong risk
factor for Alzheimer's disease. To find if HSV1 or certain other
herpesviruses are involved in vascular dementia (VaD), we searched post
mortem brain specimens from patients suffering from VaD for the presence of
HSV1, cytomegalovirus (CMV), and human herpesvirus type 6 DNA, using
polymerase chain reaction. We have found that a very high proportion of the
VaD patients, 93% (14/15), but not of age-matched normals, 34% (10/29),
harbor CMV DNA (P = 0.0002); the proportions of the patients harboring the
other viruses in brain do not differ significantly from those of the normals.
Further studies are needed to reveal whether or not the association of CMV
with VaD is causal.
PMID: 11848687 [PubMed - indexed for MEDLINE]
25-2003 — A Newborn Boy with Petechiae and Thrombocytopenia
John F. Modlin, M.D., P. Ellen Grant, M.D., Robert S. Makar, M.D., Ph.D.,
Drucilla J. Roberts, M.D., and Kalpathy S. Krishnamoorthy, M.D., M.B., B.S.
Related Articles in Medline
Articles in Medline by Author: Modlin, J. F.
Krishnamoorthy, K. S.
Presentation of Case
A newborn boy was admitted to a special-care nursery because of petechiae
The boy had been delivered at this hospital at 39 weeks' gestation to a
32-year-old woman who had had premature rupture of the membranes 16 hours
before delivery. A single dose of penicillin was administered to the mother
before vacuum-assisted delivery. The Apgar score was 9 at one minute and at
five minutes. A diffuse petechial rash, most prominent on the face and
trunk, was noted at delivery, and the baby was transferred to a newborn
The mother had never smoked, and she had not consumed alcohol after learning
of the pregnancy. Prenatal serologic tests were negative for hepatitis B
surface antigen and syphilis, positive for antibodies to rubella and for IgG
antibody to cytomegalovirus (CMV; 63 arbitrary units), and equivocal for IgM
antibody to CMV (1 arbitrary unit; <0.9 unit is a negative result, and >1.1
units a positive result). Ultrasonographic examination of the fetus at
approximately 20 weeks' gestation revealed a focus of echogenicity within
the heart and a hyperechoic bowel. Amniocentesis revealed that the
chromosomes and the level of alpha-fetoprotein were normal; the fetal cells
were negative for mutations in the cystic fibrosis gene. The estimated risk
of Down's syndrome was 1 in 85. The mother did not have a history of febrile
illness, genital lesions, or rash during the pregnancy. The family history
was unremarkable on both the maternal and the paternal sides.
The infant's temperature was 36.6°C, the pulse 110 beats per minute, and the
respiratory rate 48 breaths per minute. The blood pressure was 60/40 mm Hg.
The weight was 2.29 kg (below the 10th percentile), the length 46 cm
(between the 10th and 25th percentiles), and the head circumference 33 cm
(at the 25th percentile).
On physical examination, the infant appeared well and comfortable; his
features were not dysmorphic, and he was not in respiratory distress.
Multiple petechial lesions were present on his face, trunk, and arms and
legs and were especially numerous at the site on the head where the vacuum
cup had been placed (Figure 1). No lymphadenopathy was found. The anterior
fontanelle was open and flat. The eyes showed no microphthalmia, icterus, or
cataracts; the retinas were not examined. The clavicles were intact, and the
lungs were clear. The heart sounds were normal. The abdomen was soft; the
spleen was palpable 2.5 to 3.0 cm below the left costal margin, and the
liver edge 3.0 cm below the right costal margin. The arms and legs were well
perfused. Muscle tone was good throughout, with appropriate Moro's and
Figure 1. Photograph of the Patient, Showing Petechiae on the Forehead.
For several hours in the nursery, the infant's heart rate was in the range
of 100 to 110 beats per minute, with occasional drops to 85 beats per
minute. The arterial oxygen saturation occasionally declined from 95 percent
or more to about 85 percent. The results of laboratory tests are given in
Table 1. The levels of urea nitrogen, creatinine, total protein,
triglyceride, aspartate aminotransferase, and alanine aminotransferase were
normal. Examination of a peripheral-blood smear disclosed hypochromia (++),
with macrocytosis, polychromasia (+), and teardrop cells. Specimens of
blood, cerebrospinal fluid, and urine were obtained for culture, and
ampicillin, tobramycin, and acyclovir were given. Breast-feeding was begun.
The next day, the oxygen saturation ranged from 93 to 98 percent while the
patient was breathing ambient air.
A diagnostic procedure was performed.
Dr. John F. Modlin: May we see the prenatal radiologic studies and the
Dr. Susan A. Connolly (Radiology): An intracardiac focus of echogenicity,
which represents a small amount of calcification, usually in the papillary
muscle, was visible on a cross-section image of the fetal chest showing the
oblique four-chamber view of the heart. This finding can be a normal
variant; it is seen in 5 percent of normal fetuses on second-trimester
scans. However, it has been associated with an approximately doubled risk of
Down's syndrome. The hyperechoic bowel, which was best seen on an oblique
transverse image of the abdomen, is a finding associated with infection with
toxoplasma, CMV, togavirus (the agent that causes rubella), and herpes
simplex virus and with increased risks of Down's syndrome, cystic fibrosis,
bleeding, and growth retardation.
Dr. Stephen Walsh (Infectious Disease Unit): We were asked to see the infant
the day he was born. There was a diffuse, macular, petechial eruption on his
face but no pustules or vesicles (Figure 1).
Dr. Modlin: This newborn infant had intrauterine growth retardation and
shortly after birth was found to have hepatosplenomegaly, thrombocytopenia,
and hyperbilirubinemia. It is helpful to begin by considering the broad
categories of conditions associated with thrombocytopenia in newborns (Table
Table 2. Conditions Associated with Neonatal Thrombocytopenia.
Maternal antiplatelet antibodies are an important cause of thrombocytopenia
in newborns, but their presence is not accompanied by hepatosplenomegaly or
intrauterine growth retardation. There are no features of this case that
suggest the presence of structural birth defects such as absent radii or a
large hemangioma (the Kasabach–Merritt syndrome), and the complete blood
count is not consistent with the presence of congenital leukemia. There are
several metabolic diseases and other genetic disorders, such as Fanconi's
anemia and the Wiskott–Aldrich syndrome, that may be manifested as neonatal
thrombocytopenia, but usually not on the first day of life. This quick
process of elimination leaves infection as the probable cause of the
infant's thrombocytopenia. Early-onset bacterial sepsis was appropriately
considered in this case, and the infant underwent a workup for sepsis and
received broad-spectrum antibiotics. However, there were no risk factors for
neonatal sepsis, such as maternal fever, chorioamnionitis, or premature
labor. The normal white-cell count and the relatively benign course of
illness make this diagnosis even less likely.
The main clinical features in this case are most consistent with an
infection acquired in utero. Table 3 lists the organisms causing
intrauterine infections that might have some or all of the principal
features seen in this case — namely, thrombocytopenia, hepatosplenomegaly,
and intrauterine growth retardation.1,2,3,4,5,6 Table 3 also includes my
best estimate of the current overall incidence of each of these infections
and the likelihood that a child will have symptoms and signs at birth. CMV
is the most common agent in the differential diagnosis and thus must be
considered in any infant who is thought to have an intrauterine infection.
Congenital toxoplasmosis is the infection most likely to be confused with
CMV infection, but population-based screening in the United States indicates
that toxoplasmosis infects newborns much less often than CMV infection.
There are also distinguishing clinical features; the rash observed in
infants with congenital toxoplasmosis is usually maculopapular rather than
petechial, and infants with toxoplasmosis have chorioretinitis more often
than those with congenital CMV infection.
Table 3. Incidence of Selected Intrauterine Infections (per 100,000 Births)
in the United States.
Vertically transmitted infection with the human immunodeficiency virus (HIV)
has dropped from a peak of approximately 1600 cases in 1992 to fewer than
200 cases in 2000. In the United States, approximately 30 percent of
HIV-infected infants who are not being breast-fed acquired the infection
during gestation, but they usually have no symptoms at birth. The rare
newborns with symptomatic HIV infection have had intrauterine growth
retardation, hepatosplenomegaly, pancytopenia, diffuse leukoencephalopathy,
and early-onset Pneumocystis carinii pneumonia and have died early in
In congenital rubella, the rash tends to be more purpuric than petechial,
and cataracts and congenital heart disease are common.9 Neither of the
latter findings is present in this patient. Congenital syphilis, which is
rapidly declining in incidence in the United States, is strongly associated
with drug use by the mother. Infants with congenital syphilis have a scaly,
copper-colored, macular rash in the first weeks of life, as well as
mucous-membrane lesions and evidence of osteochondritis. Intrauterine
infections can occur with either herpes simplex virus or varicella–zoster
virus, although the former is far more likely to cause postnatal disease
after intrapartum exposure, and intrauterine infection with either virus is
rare. In most reported cases, congenital infection with herpes simplex virus
or varicella–zoster virus has resembled congenital CMV infection, but these
cases have also involved unique vesicular skin lesions or cutaneous scarring
and, in congenital varicella, hypoplasia of the limbs.10,11
CMV is a ubiquitous human herpesvirus that is the most common cause of
intrauterine infection, affecting approximately 1 percent of all newborn
infants. The fetus may become infected if a woman has a primary infection
during pregnancy or if she has reactivation of a latent infection that was
acquired before pregnancy. Although as many as 2 percent of women who are
seropositive for CMV before pregnancy will deliver an infected infant, it is
very rare for such infants to have any clinical symptoms.12,13 In contrast,
about 15 percent of infants born to women with primary infection have
clinical disease that ranges from mild to severe.14,15,16
Most primary CMV infections in pregnancy occur in the early child-bearing
years, when the rate of sexual transmission is high. The mother of this
infant was 32 years old, well beyond the age range normally associated with
primary CMV infection. It is interesting to speculate that during pregnancy,
this previously seronegative woman may have acquired the infection from an
older child who had acquired the infection in a day-care center. The rate of
CMV seroconversion in women with at least one child at home is about twice
as high as it is in women without children in the household.17 Furthermore,
horizontal transmission is responsible for the high prevalence of infection
among toddlers and preschool children who attend day-care centers.18
To summarize, the clinical and laboratory features suggest that this infant
has acquired a vertically transmitted infection in utero. Consideration of
both the epidemiologic and clinical data makes CMV infection the likely
cause, but I cannot rule out toxoplasmosis, rubella, or infection with
herpes simplex virus, varicella–zoster virus, or even HIV from the available
information. I would approach the diagnosis in two steps, looking first for
evidence of CMV infection and then testing for the other agents only if CMV
infection appears unlikely. Isolation of CMV in cell culture remains the
diagnostic standard. The virus can be isolated from several sources, but
urine is the best specimen because of the high titer of virus that is
invariably present. Many laboratories use one or more techniques to enhance
or speed the identification of virus in cell culture; one such technique is
the use of shell vials and monoclonal antibodies directed against early CMV
Dr. Nancy Lee Harris: Dr. Catlin, you cared for this patient in the newborn
nursery. Would you give us your impressions before the diagnostic procedure?
Dr. Elizabeth A. Catlin (Pediatrics): My colleagues and I considered the
causes of neonatal thrombocytopenia that Dr. Modlin has discussed and
focused primarily on infection. Congenital CMV infection seemed most likely,
given the combination of findings.
Congenital cytomegalovirus infection.
Dr. John F. Modlin's Diagnosis
Congenital cytomegalovirus infection or another infection vertically
transmitted in utero.
Dr. Harris: The diagnostic procedures were both imaging studies and a
Dr. P. Ellen Grant: Cranial ultrasonography was performed on the infant's
first day of life. A coronal image at the level of the third ventricle
showed cystic areas in the region of the germinal matrix at the
caudothalamic groove. In a more posterior region of the brain, at the level
of the atria of the lateral ventricle, there were multiple periventricular
foci of echogenicity, which were thought to represent calcifications. On
cranial computed tomographic scanning, the echogenic foci were confirmed to
be areas of calcification; many areas of calcification can be seen in a
periventricular location (Figure 2A). The distribution of these lesions is
typical of CMV infection, which has a predilection to involve the rapidly
multiplying cells of the germinal matrix. On magnetic resonance imaging, an
abnormal gyral folding pattern (affecting the right hemisphere more than the
left) is visible, and in the affected areas, the junction between the gray
matter and the white matter is irregular (Figure 2B) — these findings are
consistent with the presence of diffuse polymicrogyria. In the occipital
regions, small periventricular pseudocysts are also evident. The cerebellum
View larger version (45K):
[in this window]
[in a new window]
Figure 2. Cranial Imaging Studies.
An axial CT image of the cranium, obtained without the use of contrast
material (Panel A), shows multiple punctate, periventricular foci of
calcification (arrowheads). An axial image from a T2-weighted MRI study
(Panel B) shows multiple regions of abnormal gyral folding (arrowheads), a
finding consistent with the presence of polymicrogyria. The punctate foci of
decreased T2 signal (arrows) correspond to calcifications, which are better
seen on the CT scan. The white matter has an abnormally increased T2 signal,
and the ventricles are enlarged.
The findings on imaging — calcifications that are predominantly
periventricular, periventricular pseudocysts, polymicrogyria, and cerebellar
hypoplasia — are almost pathognomonic for CMV infection. In addition, they
tend to rule out toxoplasmosis, which is associated with enlarged ventricles
without cortical malformations, as well as other congenital infections.
Dr. Robert S. Makar: The laboratory test used in this case was a shell-vial
assay for CMV. The shell-vial assay is a variant of routine culture methods
used to detect CMV in clinical specimens. In routine culture, CMV infection
of cultured fibroblasts results in a characteristic cytopathic effect.
Although the appearance of the cytopathic effect is a sensitive marker of
viral infection, it can take several days to occur, depending on the viral
titer in the clinical specimen. In contrast, with the shell-vial assay,
virus can be detected within 24 hours after inoculation.19 In brief, glass
coverslips bearing the cultured cells are placed in vials containing culture
medium. The vials are inoculated with the specimen and then centrifuged at
low speed to facilitate viral adsorption.20 Viral infection is then detected
by indirect immunofluorescence for immediate-early antigens in the nuclei of
the cultured cells. This patient's urine was floridly positive for CMV
according to the shell-vial assay (Figure 3).
View larger version (47K):
[in this window]
[in a new window]
Figure 3. Shell-Vial Assay for Cytomegalovirus (CMV) (Immunofluorescence
Fibroblasts inoculated with the patient's urine show apple-green nuclear
staining with antibody to CMV immediate-early antigen, indicating CMV
infection. The assay was performed with reagents obtained from Chemicon
Many tests are available for the diagnosis of CMV infection, but not all of
them are reliable for the diagnosis of congenital infection. Detection of
CMV antigenemia is a sensitive test for CMV infection in immunocompromised
adults but has not been validated as a test for congenital CMV. Serologic
tests for fetal IgG and IgM antibodies against CMV are difficult to
interpret. Since IgG antibodies are passively transferred from mother to
fetus, a positive anti-CMV IgG titer in fetal blood is not meaningful. Anti-CMV
IgM antibodies do not cross the placenta, and their presence in cord blood
suggests congenital infection. However, the sensitivity and specificity of
currently available tests for IgM antibodies do not yet match those of
viral-culture methods or polymerase-chain-reaction (PCR) assays for viral
genetic material.1 Thus, the diagnosis of congenital CMV infection hinges on
the detection of virus by one of the latter two methods. Clinical specimens
should be obtained within two weeks after birth to allow congenital and
perinatal infections to be distinguished from one another.
Prenatal diagnosis of congenital CMV infection can be offered to women in
whom seroconversion occurs during pregnancy. The isolation of virus or viral
DNA from amniotic fluid is the most reliable measure of congenital
infection.1 However, a negative result may not rule out infection, even when
the sample of amniotic fluid is obtained after 20 weeks of gestation,21 and
a positive result does not necessarily correlate with symptomatic
infection.22 A recent study suggests that a high CMV load in the amniotic
fluid on quantitative PCR is correlated with symptomatic infection23 and
thus may be useful as a prognostic tool in congenital CMV infection.
Dr. Harris: As is the routine when an infant is born ill, the placenta was
examined in this case, and I would like to ask Dr. Drucilla Roberts to
describe the findings.
Dr. Drucilla J. Roberts: The placenta was a small, singleton placenta; it
weighed 310 g (below the 10th percentile for 39 weeks' gestation) and was
discolored (greenish-brown) by meconium pigment. At least 50 percent of the
villi were avascular, with open maternal vascular spaces (Figure 4). This
finding represents vascular compromise from the fetal (not maternal)
circulation to the placenta.24
View larger version (51K):
[in this window]
[in a new window]
Figure 4. Histologic Section of the Placenta (Hematoxylin and Eosin, x250).
Avascular villi (arrow), with open maternal vascular spaces (arrowhead), are
The pathological differential diagnosis of avascular villi (Table 4)
includes chronic villitis, either active or healed.25 Chronic villitis,
which is seen in up to 10 percent of all placentas examined histologically,
is characterized by a maternal inflammatory infiltrate, typically
mononuclear, in the villi. Most cases are thought to be due to a maternal
factor (perhaps an immune response to the fetal allograft). A small number
of cases are due to transplacental infection, with CMV being the most common
Table 4. Pathological Differential Diagnosis of Avascular Villi.
The histopathological features of CMV placentitis include lymphoplasmacytic
villitis, sclerosis of the villous capillaries, chorionic vessel thromboses,
necrotizing villitis, hemosiderin deposition in the villous stroma, and
immature nucleated fetal red cells in the blood vessels and viral inclusions
(seen in approximately 10 percent of cases).26 In the infant in the current
case, there was no active chronic villitis, none of the features of an
active CMV placentitis were present, and immunohistochemical stains for CMV
antigen were negative.27
Infants with a remote transplacental CMV infection often have nonspecific
findings of villous sclerosis and chorionic vascular thromboses, and the
weight of their placentas may be below the 10th percentile. The placental
pathological findings in this case are consistent with a CMV villitis that
developed at least two weeks before birth and possibly earlier and that has
scarred, leaving the avascular sclerotic villi.
Dr. Harris: Since we assumed that the diagnosis in this case would not be a
problem for Dr. Modlin, I asked him to tell me his diagnosis before the
conference and then invited him to discuss current issues in the management
of congenital CMV infection.
Discussion of Management
Dr. Modlin: The case under discussion is representative of the approximately
10 percent of CMV-infected newborns who have clinical evidence of disease in
the neonatal period. The severity of the infection appears to be related to
the age of the fetus at the time of the infection: those infected during the
first trimester have relatively severe consequences, whereas those infected
during the third trimester may have no symptoms. The spectrum of signs and
symptoms includes premature delivery, intrauterine growth retardation,
microcephaly, jaundice, petechiae, hepatosplenomegaly, thrombocytopenia,
indirect and direct hyperbilirubinemia, and other signs of mild hepatitis
Table 5. Selected Clinical and Laboratory Findings in 106 Infants with
Symptomatic Intrauterine Congenital Cytomegalovirus Infection in the
The mortality rate is approximately 20 percent. For those who survive, the
hematologic abnormalities, hepatitis, and other manifestations not involving
the central nervous system resolve within weeks to months after birth,
despite ongoing shedding of the virus, which persists for months to years
after birth.28 However, about 60 percent of these infants have sensorineural
hearing deficits, and in about 70 percent microcephaly, seizures, motor
abnormalities, developmental delay, or other cognitive impairments occur.29
Overall, 90 percent of the surviving infants will have either a sensory
deficit or cognitive impairment.
Although the initial insult occurs in utero, the developing central nervous
system remains vulnerable to damage from persistent viral replication after
birth, and thus effective antiviral therapy given after birth may reduce the
severity of the neurologic damage and improve the long-term outcome.30,31
The first opportunity to test this hypothesis came with the development of
ganciclovir, a derivative of acyclovir, which was the first antiviral agent
capable of inhibiting CMV replication at clinically attainable
concentrations. The Collaborative Antiviral Study Group of the National
Institute of Allergy and Infectious Diseases recently completed a phase 3
trial of intravenous ganciclovir for symptomatic congenital CMV disease in
infants.32 This challenging trial required the parents of infants with a
devastating prognosis to accept random assignment to treatment with
ganciclovir or no treatment and required the placement of a central venous
catheter and twice-daily intravenous treatment. The infants who were
randomly assigned to a six-week course of intravenous ganciclovir had
significantly better hearing and more rapid resolution of hepatitis than the
infants who were not treated.
These unequivocal results provide proof of concept and allow us to proceed
to studies designed to optimize antiviral therapy for CMV-infected newborns.
A planned Collaborative Antiviral Study Group trial will evaluate
longer-term treatment with valganciclovir, a recently licensed prodrug that
reaches serum concentrations similar to those of ganciclovir when given
orally. If this study shows that valganciclovir is effective in further
reducing the morbidity associated with symptomatic congenital CMV infection,
then it follows that treatment of the 90 percent of infected infants who
have no symptoms at birth but who have a lower but well-documented risk of
hearing loss than those with signs of infection at birth will be the target
of further antiviral research.1 In turn, this would raise a brand-new issue
for those who study the feasibility and outcomes of newborn screening and
perform cost–benefit analyses. At this moment, the future for the diagnosis
and treatment of congenital CMV infections looks very promising.
Dr. Harris: Dr. Walsh will discuss the treatment decision that was made in
the current case.
Dr. Walsh: We reviewed the published phase 2 data on the use of intravenous
ganciclovir for congenital CMV infection33 and contacted a colleague at the
University of Alabama at Birmingham, who shared with us preliminary data
from the phase 3 trial of ganciclovir.29 The data were particularly
encouraging with respect to the stabilization of hearing loss. We then
discussed treatment options with the parents of the infant in this case, and
they opted to have their infant receive intravenous ganciclovir for six
weeks. Therapy was completed without serious complications.
Dr. Harris: Dr. Casavant, you are this patient's primary care physician and
have been working with the family during the administration of treatment at
home. Would you discuss some of the issues and tell us how the patient is
Dr. David W. Casavant (Pediatrics): After the diagnosis was established,
further evaluation showed mild CMV-associated chorioretinitis and profound
hearing loss in the left ear. The ganciclovir treatment required placement
of a central venous catheter and twice-weekly testing of blood samples to
monitor the complete blood count for evidence of neutropenia or anemia,
since ganciclovir is toxic to the bone marrow. One of the parents' chief
problems during the first months after the infant's birth was the fear of
other family members that they or their children might be infected by the
infant. We tried to assure them that CMV infection is quite common and is
not associated with problems in immunocompetent persons, when acquired after
the neonatal period.
Although the literature forecasts a rather bleak picture for the patient's
development, he has done remarkably well. At his most recent routine visit,
he was approximately 22 weeks old and had only mild left-sided weakness and
some resolving torticollis.
Dr. Harris: This patient was evaluated and followed by Dr. Krishnamoorthy.
Dr. Krishnamoorthy, would you review the neurologic complications of
congenital CMV infection and tell us about this patient's neurologic status
Dr. Kalpathy S. Krishnamoorthy: Neonates with CMV infection can be divided
into three prognostic groups. Up to 95 percent of those with overt
manifestations in the central nervous system (e.g., microcephaly, cerebral
calcification, or chorioretinitis) have major neurodevelopmental sequelae;
those with only systemic manifestations (e.g., jaundice, petechiae, or
hepatosplenomegaly) are still at risk but have a slightly better prognosis;
and those with neither central nervous system nor systemic manifestations
have the best prognosis. However, even infants with no symptoms are at risk
for developmental delay, microcephaly, motor deficits, and (most commonly)
sensorineural hearing loss, which may not become apparent until late infancy
or early childhood.34 An important clinical point is that congenital CMV
infection should be included in the differential diagnosis of developmental
delay associated with microcephaly and sensorineural hearing loss during
infancy, even in the absence of neonatal manifestations of CMV infection.
Microcephaly is the most specific predictor of mental retardation and major
motor disability. In a recent study,35 the combination of microcephaly and
abnormal findings on CT imaging carried the worst prognosis (mean IQ score,
<50; major motor deficit in 75 percent of the patients); a normal head
circumference and normal CT findings were associated with a good prognosis
(mean IQ score, >90; no major motor deficit); and a normal head
circumference and abnormal CT findings were associated with an intermediate
prognosis (mean IQ score, 70 to 80; major motor deficit in 37 percent).
In view of the abnormalities seen on CT scanning in this infant, he falls
into the intermediate prognostic group. We have seen him twice in follow-up,
most recently when he was 14 weeks of age. His head circumference has stayed
at the 25th percentile, which is in line with his overall size. He remains
visually alert and sociable and has a good smile. Assessment of muscle tone
shows diffuse, mild hypertonia that is manifested as prominent clenching of
the fists and excessive arching of the back. Left-sided sensorineural
hearing loss persists, but the ophthalmologic findings remain normal. His
prognosis remains uncertain.
Dr. Grant: The presence of polymicrogyria on the imaging studies suggests
that the major injury to the fetal brain occurred somewhere between 20 and
25 weeks' gestational age. Would it have been possible to treat the mother
when she seroconverted?
Dr. Modlin: The usual problem is detecting infection in the pregnant woman,
because the majority of these infections are completely silent.
Unfortunately, it is not clear that there is an effective and safe prenatal
treatment for fetal CMV infection.
Dr. Casavant: Because of the mother's equivocal IgM response to CMV in the
presence of IgG antibodies, the possibility of recent infection was
discussed with her early in the pregnancy. However, there are no guidelines
for treatment of CMV infection during pregnancy.
Congenital cytomegalovirus infection.
We are indebted to Dr. Elizabeth Catlin for assistance in preparing the case
abstract and to Dr. Mark Pasternack for assistance in organizing the
From the Departments of Pediatrics and Medicine, Dartmouth–Hitchcock Medical
Center and Dartmouth Medical School, Lebanon, N.H. (J.F.M.); the Departments
of Radiology (P.E.G.), Pathology (R.S.M., D.J.R.), and Pediatrics (K.S.K.),
Massachusetts General Hospital and Harvard Medical School.
Spagno S. Cytomegaloviruses. In: Remington JS, Klein JO, eds. Infectious
diseases of the fetus and newborn infant. 5th ed. Philadelphia: W.B.
Weller TH, Hanshaw JB. Virologic and clinical observations on cytomegalic
inclusion disease. N Engl J Med 1962;266:1233-1244.[ISI]
Guerina NG, Hsu H-W, Meissner HC, et al. Neonatal serologic screening and
early treatment for congenital Toxoplasma gondii infection. N Engl J Med
Eberhardt MS, Ingram DD, Makuc DM, et al. Urban and rural health chartbook.
Health, United States, 2001. Hyattsville, Md.: National Center for Health
Congenital syphilis -- United States, 2000. MMWR Morb Mortal Wkly Rep
Reyes MP, Hunt N, Ostrea EM Jr, George D. Maternal/congenital syphilis in a
large tertiary-care urban hospital. Clin Infect Dis 1993;17:1041-1046.[ISI][Medline]
Millard DD, Chadwick EG, Yogev R, Modlin JF. Zidovudine treatment of an
infant with congenital human immunodeficiency virus infection. Pediatr
Infect Dis J 1990;9:929-931.[ISI][Medline]
Rudin C, Meier D, Pavic N, et al. Intrauterine onset of symptomatic human
immunodeficiency virus disease. Pediatr Infect Dis J 1993;12:411-414.[ISI][Medline]
Cooper LZ, Green RH, Krugman S, Giles JP, Mirick GS. Neonatal
thrombocytopenic purpura and other manifestations of rubella contracted in
utero. Am J Dis Child 1965;110:416-427.[ISI][Medline]
Hutto C, Arvin A, Jacobs R, et al. Intrauterine herpes simplex virus
infections. J Pediatr 1987;110:97-101.[ISI][Medline]
Alkalay AL, Pomerance JJ, Rimoin DL. Fetal varicella syndrome. J Pediatr
Stagno S, Reynolds DW, Huang E-S, Thames SD, Smith RJ, Alford CA Jr.
Congenital cytomegalovirus infection: occurrence in an immune population. N
Engl J Med 1977;296:1254-1258.[Abstract]
Stagno S, Pass RF, Dworsky ME, Alford CA Jr. Maternal cytomegalovirus
infection and perinatal transmission. Clin Obstet Gynecol
Stagno S, Pass RF, Cloud G, et al. Primary cytomegalovirus infection in
pregnancy: incidence, transmission to fetus, and clinical outcome. JAMA
Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. Intrauterine
transmission of cytomegalovirus to infants of women with preconceptional
immunity. N Engl J Med 2001;344:1366-1371.[Abstract/Full Text]
Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of
congenital cytomegalovirus infection in relation to maternal antibody
status. N Engl J Med 1992;326:663-667.[Abstract]
Dworsky ME, Welch K, Cassady G, Stagno S. Occupational risk for primary
cytomegalovirus infection among pediatric health-care workers. N Engl J Med
Adler SP. Cytomegalovirus transmission among children in daycare, their
mothers and caretakers. Pediatr Infect Dis J 1988;7:279-285.[ISI][Medline]
Hodinka RL, Friedman HM. Human cytomegalovirus. In: Murray PR, Baron EJ,
Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. 6th
ed. Washington, D.C.: ASM Press, 1995:884-94.
Gleaves CA, Smith TF, Shuster EA, Pearson GR. Rapid detection of
cytomegalovirus in MRC-5 cells inoculated with urine specimens by using
low-speed centrifugation and monoclonal antibody to an early antigen. J Clin
Azam A, Vial Y, Fawer CL, Zufferey J, Hohlfeld P. Prenatal diagnosis of
congenital cytomegalovirus infection. Obstet Gynecol 2001;97:443-448.[CrossRef][ISI][Medline]
Lazzarotto T, Guerra B, Spezzacatena P, et al. Prenatal diagnosis of
congenital cytomegalovirus infection. J Clin Microbiol
Guerra B, Lazzarotto T, Quarta S, et al. Prenatal diagnosis of symptomatic
congenital cytomegalovirus infection. Am J Obstet Gynecol 2000;183:76-82.[ISI][Medline]
Roberts D, Schwartz RS. Clotting and hemorrhage in the placenta -- a
delicate balance. N Engl J Med 2002;347:57-59.[Full Text]
Gersell DJ. Chronic villitis, chronic chorioamnionitis, and maternal floor
infarction. Semin Diagn Pathol 1993;10:251-266.[ISI][Medline]
Benirschke K, Mendoza GR, Bazeley PL. Placental and fetal manifestations of
cytomegalovirus infection. Virchows Arch B Cell Pathol 1974;16:121-139.
Muhlemann K, Miller RK, Metlay L, Menegus MA. Cytomegalovirus infection of
the human placenta: an immunocytochemical study. Hum Pathol
Stagno S, Pass R, Dworsky ME, Alford CA. Congenital and perinatal
cytomegalovirus infections. Semin Perinatol 1983;7:31-42.[ISI][Medline]
Kimberlin DW, Lin CY, Sanchez P, et al. Ganciclovir (GCV) treatment of
symptomatic congenital cytomegalovirus (CMV) infections: results of a phase
III randomized trial. Presented at the 40th Interscience Conference on
Antimicrobial Agents and Chemotherapy, Toronto, September 17–20, 2000.
Kimberlin DW. Antiviral therapy for cytomegalovirus infections in pediatric
patients. Semin Pediatr Infect Dis 2002;13:22-30.[CrossRef][Medline]
Whitley RJ, Kimberlin DW. Treatment of viral infections during pregnancy and
the neonatal period. Clin Perinatol 1997;24:267-283.[ISI][Medline]
Kimberlin DW, Lin C-Y, Sanchez PJ, et al. Effect of ganciclovir therapy on
hearing in symptomatic congenital cytomegalovirus disease involving the
central nervous system: a randomized, controlled trial. J Pediatr (in
Whitley RJ, Cloud G, Gruber W, et al. Ganciclovir treatment of symptomatic
congenital cytomegalovirus infection: results of a phase II study. J Infect
Fowler KB, McCollister FP, Dahle AJ, Boppana S, Britt WJ, Pass RF.
Progressive and fluctuating sensorineural hearing loss in children with
asymptomatic congenital cytomegalovirus infection. J Pediatr
Noyola DE, Demmler GJ, Nelson CT, et al. Early predictors of
neurodevelopmental outcome in symptomatic congenital cytomegalovirus
infection. J Pediatr 2001;138:325-331.[CrossRef][ISI][Medline]
"Even though SV-40 was being screened out,
scientists such as John Martin, a professor of pathology at the University
of Southern California, warned that other monkey viruses could be dangerous.
But government officials rebuffed Martin's attempt to research those risks
back in 1978 and again in 1995 when he was denied federal funding and
vaccine samples he needed to investigate the effects of simian
cytomegalovirus (SCMV), an organism that his studies indicate causes
neurological disorders in the human brain."--Money Magazine
1 MMR/HHV-6: general considerations
>>> Posting number 25001,
dated 2 Oct 1997 14:37:47
Here are some thoughts about MMR and HHV-6. We must keep in mind that
each child is different and that the timing during which a child might
have acquired HHV-6 will differ from person to person. Therefore, the
following comments should be taken as a general sketch, a starting point
in trying to understand each child's specific case. We must also keep in
mind that, in many individuals, there may be more than one virus,
bacteria, and/or fungus present; and this kind of inter-individual
variation is likely to be seen as differences in each child's specific
traits and medical history. So, here are some thoughts centered upon MMR
and HHV- 6.
1. Measles and measles vaccinations induce immunospression. This is
well known, well documented; and a primary researcher in this is Diane E.
Griffin of JohnsHopkins. (Cites will be in subseqeunt post).
2. HHV-6 is ubiquitous, many kids have it and handle it quite OK.
However, HHV-6 is also known to induce high fever and/or seizures in a
goodly number of kids. The healthier a given child's immune system, the
likelier that HHV-6 will not cause problems to that child.
3. At least hypothetically, the immunosuppression that accompanies
measles vaccination would allow HHV-6 to blossom more fully within the
child. What might be seen is roseola (aka exanthema subitum) and/or
fevers and/or some mild or not so mild febrile convulsions. (some HHV-6
cites will be posted separately too).
4. HHV-6 is also known to be able to produce its own immunosuppression,
and can even find its way into bone marrow. In some children, the HHV-6
immunosuppression would become additive with the immunosuppression
already induced by the measles component of the MMR vaccination.
5. Giving MMR prior to the age of 12 months would seem to be a way to
ensure aprolonged Transient Hypogammaglobulinemia of Infancy (pTHI),
thereby inducing another kind of double immunosuppression -- that from
the infant's normal THI plus that from measles-vaccination
6. If a pregnant woman were to receive a measles vaccination, then her
measles-related immunosuppression would increase the likelihood that
other viruses, bacteria, and/or fungi would gain a foothold or (if
present and normally immunosuppressed) to blossom in ways affecting fetal
7. The work of Tasnee Chonmaitree and colleagues has demonstrated that
many cases of recurrent otitis media (rOM) are viral in origin. In a
study of 271 kids with rOM, 10 percent were found to have cytomegalovirus
and/or herpes simplex virus in middle ear effusion (CMV, HSV, MEM). Her
studies prove that, in some kids, heavy duty viruses can be present at an
early age, even if the only symptom is rOM.
8. HHV-6, CMV, and Epstein-Barr virus (EBV) are known to be able to
induce immunosuppression. When Drs. Baker and Martin find CMV in
peripheral blood, that is a very important finding. Treating the CMV and
reducing it or eliminating it can only help the child -- even if he or
she has other viruses in the CNS, viruses that may not be
detectable by peripheral measures or even via viral culture of CSF.
9. If an infant has any of these viruses (eg, HHV-6, CMV, or EBV) in
his or her system when the MMR is given, then (due to the
immunosuppressivity of the measles component) that child would seem at
risk for any of the three immunosuppressive viruses to become more
entrenched and active.
10. HSV is a very special virus. It is present in some kids with
recurrent otitis media (rOM), yet may remain within the CNS with *no*
exterior symptoms one the otitis has subsided. Depending upon its route
of entry (eg, oral/gastrointestinal, nasal-cativy, scraped skin, etc),
HSV will travel to various parts of the peripheral and central nervous
systems. Once there, if a child is immunocompetent, the virus may remain
latent and, while latent, may induce no neuronal death.
11. If HSV is latently present in CNS neurons when the MMR is given,
two effects are likely: (i) the measles-induced immunosupression may
allow some of the latent HSV to become re-activated, and (ii) the MMR's
induction of interferon gamma (1) ought lead to MHC-I presentation of
viral particles upon the surface of neurons, which would then be killed
by the person's own immune surveillance processes. Importantly, HSV is
capable of migrating to neural substrates that have been identified in
autism (eg, cerebellum and temporal lobe) and/or that participate in
autistic traits -- eg, neuronal regions subserving language,
emotions, sensory sensitivities, and direct eye-contact.
Each child is very different; each child's medical history prior to,
during, and subsequent to the MMR is very different and ought be
considered as the tapestry in which the MMR and HHV-6 occurred.
Several parental anecdotes have mentioned the temporal sequence MMR
followed by signs of HHV-6. This is an extremely important relationship,
and possible causal links were outlined in the first portion of this
document. However, each parent would be well served to look for
additional clues prior to and subsequent to the vaccination. Such
introspection may generate additional clues instructive regarding the
child's specific pathogenesis into autism and, most importantly, may
clues towards designing the most effective treatments.
In other words, the link "MMR and HHV-6" is important, but each
child's medical history may have some additional clues that can be
considered --eg, familial infections such as mononucleosis or herpes or?
eg, gastrointestinal problems in the child and/or in other members of the
family or ? eg, other?
These developments are very exciting and are occurring because of each
person's committment to ask questions and to share. From the pioneers
such as Rimland, Baker, Pangborn, Martin and others, to the parents and a
few researchers, and a growing number of parents-as-researchers, might we
say, Progress is being made and shall continue!
1) Pabst HF et al. Kinetics of immunologic responses after primary MMR
vaccination. Vaccine. 15(1):10-4, 1997 Jan. "To study the kinetics of
humoral as well as cellular immunity to measles and to test for
associated immunosuppression 124 12 month old children were studied
twice, before routine MMR and either 14, 22, 30, or 38 days after
vaccination...Interferon-gamma was the principal cytokine produced after
primary measles immunization..."
2 MMR/HHV-6: immune suppression by measles virus/vaccine
>>> Posting number 25023,
dated 2 Oct 1997 20:15:14
Measles virus can induce immune suppression, by vaccinations and/or
infection. The first seven citations are by DE Griffin and colleagues.
Cites 8 thru 10 are by other groups researching immunosuppression caused
by measles virus, whether the "wild-type" or the type found in certain
<1> Karp CL. Wysocka M. Wahl LM. Ahearn JM. Cuomo PJ. Sherry B.
Trinchieri G. Griffin DE.
Mechanism of suppression of cell-mediated immunity by measles virus
Science. 273(5272):228-31, 1996 Jul 12.
<2> Hussey GD et al.
The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune
response in infants.
Journal of Infectious Diseases. 173(6):1320-6, 1996 Jun.
<3> Auwaerter PG et al Changes within T cell receptor V beta subsets in
measles vaccination. Clinical Immunology & Immunopathology.
79(2):163-70, 1996 May.
<4> Griffin DE. Immune responses during measles virus infection.
Current Topics in Microbiology & Immunology. 191:117-34, 1995.
<5> Ward BJ. Griffin DE.
Changes in cytokine production after measles virus vaccination:
predominant production of IL-4 suggests induction of a Th2 response.
Clinical Immunology & Immunopathology. 67(2):171-7, 1993 May.
<6> Wu VH. McFarland H. Mayo K. Hanger L. Griffin DE. Dhib-Jalbut
Measles virus-specific cellular immunity in patients with vaccine
Journal of Clinical Microbiology. 31(1):118-22, 1993 Jan.
<7> Griffin DE et al
In vitro studies of the role of monocytes in the immunosuppression
associated with natural measles virus infections. Clinical
Immunology & Immunopathology. 45(3):375-83, 1987 Dec.
<8> Schnorr JJ et al.
Induction of maturation of human blood dendritic cell precursors by
measles virus [vaccine & wild type] is associated with immunosuppression.
Proc of the National Acad of Sciences USA 94(10):5326-31 1997. As
well as inducing a protective immune response against reinfection,
acutemeasles is associated with a marked suppression of immune functions
against superinfecting agents and recall antigens, and this association
is the major cause of the current high morbidity and mortality rate
associated with measles virus (MV) infections. Dendritic cells (DCs) are
antigen-presenting cells crucially involved
in the initiation of primary and secondary immune responses, so we set
out to define the interaction of MV with these cells. We found that both
mature and precursor human DCs generated from peripheral blood monocytic
cells express the major MV protein receptor CD46 and are highly
susceptible to infection with both MV vaccine (ED) and wild-type (WTF)
strains, albeit with different kinetics. Except for the
down-regulation of CD46, the expression pattern of functionally
important surface antigens on mature DCs was not markedly altered after
MV infection. However,precursor DCs up-regulated HLA-DR, CD83, and
CD86 within 24 h of WTF infection and 72 h after ED infection, indicating
their functional maturation. In addition, interleukin 12 synthesis was
markedly enhanced after both ED and WTF infection in DCs. On the other
hand, MV-infected DCs strongly interfered with mitogen-dependent
proliferation of freshly isolated peripheral blood lymphocytes in
vitro. These data indicate that the differentiation of effector functions
of DCs is not impaired but
rather is stimulated by MV infection. Yet, mature, activated DCs
expressing MV surface antigens do give a negative signal to inhibit
lymphocyte proliferation and thus contribute to MV-induced
<9> Aaby P.
Assumptions and contradictions in measles and measles immunization
research: is measles good for something?. Social Science &
Medicine. 41(5):673-86, 1995 Sep. Measles infection, the major cause
of childhood mortality among infections preventable by immunization, has
been considered to kill mainly young and malnourished children. Assuming
that mainly 'weak' children are saved by immunizations, it has been
speculated that the impact on survival of immunization is likely to
be limited because the malnourished children are more prone to die of
other infections. However, recent studies from developing countries have
suggested that host factors may not be the most important determinants of
acute and long-term mortality after measles infection. Instead, it was
found that infection contracted after exposure at home infection
contracted from someone outside the home.
Furthermore, measles is particularly severe if contracted from
someone of the opposite sex. Hence transmission factors, in particularly
intensity of exposure and cross-sex transmission, may be more important
determinants of measles mortality than the determinants of measles
mortality than the host factors usually emphasized. Consistent with these
observations and in contrast to assumptions
about 'weak' children dying, immunization is associated with a major
reduction in mortality.Since measles immunization is associated with a
30% reduction in mortality or more, the impact is much larger than should
be expected from the proportion of all deaths attributed to measles. It
has therefore been suggested that measles immunization may prevent the
persistent immunosuppression and delayed mortality assumed to
beassociated with measles. However, several observations contradict the
common understanding that the function of measles immunization is only to
prevent the acute and long-term mortality associated with measles
infection. Recently, the high-titre measles immunization recommended by
WHO was found to be associated
with reduced survival for female recipients compared with girls who have
received the standard low-dose measles vaccine, and this difference in
survival was not due to suboptimal protection against measles infection.
Contrary to usual assumptions. against measles infection. Contrary to
usual assumptions, standard low-dose measles vaccine reduces mortality
even more when given before 9 months of age, the age currently
recommended by WHO. The beneficial impact of standard vaccine is
apparently temporary, lasting 1 to 2 years, whereas it should increase
with the age of the child. The beneficial effect seems to be particularly
strong for girls. The most likely interpretation of these
observations, is that standard low-dose measles vaccine has a
non-specific beneficial effect. Contrary to current assumptions, children
who survive the acute phase of measles infection may have a survival
advantage compared with unimmunized, uninfected children...
<10> Smedman L et al.
Immunosuppression after measles vaccination.
Acta Paediatrica. 83(2):164-8, 1994 Feb.
The influence of conventional live attenuated measles vaccine on
cellular immune responsiveness was investigated in Sweden and
Guinea-Bissau. Sixteen children in a residential area in Bissau and 16
living in southern Stockholm were examined before and 8-10 days after
vaccination... These observations may be relevant to the increased
mortality found in children immunized with high-titre
measles vaccines, as compared to controls, in recent studies...
J Autism Dev Disord. 2004 Oct;34(5):583-6.
Brief report: autistic disorder in three children
with cytomegalovirus infection.
Sweeten TL, Posey DJ, McDougle CJ.
Department of Psychiatry, Indiana University School
of Medicine, Indianapolis, IN 46202-4800, USA.
Previous research has identified a
relationship between autistic disorder (autism) and specific congenital
infections. Three cases of congenital or perinatal cytomegalovirus (CMV)
infection occurring in association with autism are described.
Hypothetical mechanisms relating congenital infection, such as CMV, to
the development of autism are discussed. A better understanding of the
immunologic response to certain congenital infections may provide
important information pertaining to the pathophysiology and etiology of
autism in vulnerable individuals.
Subject: Cytomegalovirus infection and development of allergic diseases
J Allergy Clin Immunol. 2004 Dec;114(6):1434-40.
Cytomegalovirus infection and development of allergic diseases in early
childhood: interaction with EBV infection?
Sidorchuk A, Wickman M, Pershagen G, Lagarde F, Linde A.
Institute of Environmental Medicine, Stockholm, Sweden.
BACKGROUND: Chronic replication of cytomegalovirus and EBV in early life may
affect the immune system and play a role in the development of allergy in
children. OBJECTIVE: To assess the relation between cytomegalovirus
infection and allergic disorders in children, including a possible
interaction with EBV infection. METHODS: From a prospective birth cohort
study in Stockholm, on factors of importance for development of allergy,
2581 four-year-old children were enrolled. The classification of allergic
diseases was based on questionnaire answers and determination of IgE
antibodies to common airborne and food allergens. IgG to cytomegalovirus was
determined by a commercial ELISA and to EBV by indirect immunofluorescence.
RESULTS: A total of 1191 (46%) children were cytomegalovirus-seropositive.
There were no significant associations between seropositivity to
cytomegalovirus and allergic manifestations, such as bronchial asthma,
suspected allergic rhinitis, or atopic dermatitis. Seropositivity to
cytomegalovirus alone, ie, without seropositivity to EBV, was related to IgE
antibodies to airborne and food allergens (adjusted odds ratio, 1.8; 95% CI,
1.2-2.9). An antagonism between cytomegalovirus and EBV in relation to
sensitization to airborne and food allergens was suggested ( P = .05).
CONCLUSION: The study does not support the hypothesis that previous
cytomegalovirus infection plays an important role in the pathogenesis of
bronchial asthma, suspected allergic rhinitis, or atopic dermatitis in
children. However, in the absence of EBV infection, cytomegalovirus
infection may be related to sensitization to airborne and food allergens.
Lopez-Pison J, Rubio-Rubio R, Urena-Hornos T, Omenaca-Teres M, Sans A,
Cabrerizo de Diago R, Pena-Segura JL. Retrospective diagnosis of congenital
infection by cytomegalovirus in the case of one infant. Rev Neurol.
Sweeten TL, Posey DJ, McDougle CJ. Brief report: autistic disorder in three
children with cytomegalovirus infection. J Autism Dev Disord. 2004;
Yamashita Y, Fujimoto C, Nakajima E, Isagai T, Matsuishi T. Possible
association between congenital cytomegalovirus infection and autistic
disorder. J Autism Dev Disord. 2003;33:455-9.
Ivarsson SA, Bjerre I, Vegfors P, Ahlfors K. Autism as one of several
disabilities in two children with congenital cytomegalovirus infection.
Stubbs EG, Ash E, Williams CP. Autism and congenital cytomegalovirus. J
Autism Dev Disord. 1984;14:183-9.
Markowitz PI. Autism in a child with congenital cytomegalovirus infection. J
Autism Dev Disord. 1983;13:249-53.
Stubbs EG. Autistic symptoms in a child with congenital cytomegalovirus
infection. J Autism Child Schizophr. 1978;8:37-43.
It is also known that up to 20% of cytomegalovirus infected blood samples
will test negative using routine antibody based assays (Rahbar AR, Sundqvist
VA, Wirgart BZ, Grillner L, Soderberg-Naucler C. Recognition of
cytomegalovirus clinical isolates by sera from cytomegalovirus-negative
blood donors. Transfusion 2004; 44: 1059-66.) The polymerase chain reaction
(PCR) also has limitations, especially in detecting stealth-adapted
cytomegaloviruses. By far the best screening test for both regular and
stealth-adapted cytomegaloviruses is virus culture. I know from my own
experience that the majority of autistic children have evidence of
circulating cell damaging viruses (Martin WJ. Stealth virus isolated from an
autistic child. J Autism Dev Disord. 1995;25:223-4.)
Parents have a right to expect Public Health authorities to perform
appropriate virus cultures on autistic children. As I have said previously
“If autism is epidemic, why not look for an infectious cause?”
The Government’s obligation to pursue cytomegalovirus infection is further
strengthened by FDA’s own published data that 3 of 8 licensed polio virus
vaccines released in the mid 1970’s contain DNA of African green monkey
simian cytomegalovirus (Sierra-Honigmann AM, Krause PR. Live oral poliovirus
vaccines and simian cytomegalovirus. Biologicals. 2002;30:167-74.)
Additional information is available at www.s3support.com Kind regards, W.
John Martin, M.D., Ph.D.
Vet Pathol 41:108-115 (2004)
© 2004 American
College of Veterinary Pathologists
Cervical and Vaginal Epithelial Neoplasms in Cynomolgus
C. E. Wood, H. Borgerink, T. C.
Register, L. Scott and J. M. Cline
Comparative Medicine Clinical Research Center, Wake
Forest University Health Sciences, Winston-Salem, NC
Papillomavirus-associated cervical cancer is the second most
common neoplasm in women but has rarely been reported in animals.
This report describes cervical and vaginal intraepithelial neoplasms
identified in routine histologic specimens obtained from 20
(5.2%) of 385 female cynomolgus macaques (Macaca fascicularis)
being used in long-term studies. Lesion incidence was similar
in both control and hormonally treated animals (4.7% and 5.5%,
respectively). Neoplasms included benign vaginal papillomas,
mild to severe intraepithelial dysplasias, and two invasive
cervical carcinomas. Common morphologic features included koilocytosis,
nuclear atypia, and expansion of the basal epithelium. Selective
staining of lesions with at least one of three papillomavirus
antibodies was observed in all cases (20 of 20). In contrast,
immunostaining of lesions was negative for Epstein-Barr–related
virus proteins (0 of 20). The unique similarities between the
observed lesions and those seen in women suggest that macaques
may provide a suitable animal model for study of papillomavirus
Key words: Cervical intraepithelial neoplasia;
immunohistochemistry; Macaca fascicularis; nonhuman primates;
Request reprints from Dr. C. E. Wood, Comparative Medicine Clinical
Research Center, Wake Forest University Health Sciences, Medical Center
Boulevard, Winston-Salem, NC 27157-1040 (USA). E-mail:
Return to page